Muscular atrophy inhibitor and method for inhibiting muscular atrophy
The present invention is a muscular atrophy inhibitor comprising at least one pyrimidine nucleotide or a precursor thereof as an active ingredient. Also, the present invention is a method for inhibiting muscular atrophy by administrating at least one pyrimidine nucleotide or a precursor thereof.
1 . A method for inhibiting muscular atrophy in an individual in need thereof, wherein the method comprises;
(a) providing a formulation or a pharmaceutical comprising:
(i) cytidine or a cytidylic acid salt;
(ii) uridine or uridylic acid salt;
(iii) cytidine and uridine; or
(iv) cytidylic acid or a cytidylic acid salt, and uridylic acid or a uridylic acid salt; and
(b) administrating to the individual in need thereof the formulation or pharmaceutical of (a).
2 . The method for inhibiting muscular atrophy according to claim 1 , wherein the formulation or pharmaceutical is formulated for enteral or parenteral administration, and the formulation is enterally or parenterally administered.
3 . The method according to claim 1 , wherein the formulation or pharmaceutical is formulated for oral administration and is orally administered.
4 . The method according to claim 1 , wherein the oral formulation or pharmaceutical is formulated as a tablet, a granule, a capsule, a dispersions, a solution, a syrup, an emulsion, an injection, a supplement or a spray.
5 . The method of claim 1 , wherein the formulation or pharmaceutical is formulated for injection, or for administration as a spray, ointment or patch, and is administered by injection, or by spraying, or use application as an ointment, paste or patch.
6 . The method of claim 1 , wherein the formulation or pharmaceutical further comprises: an excipient, a binder, a disintegrant, a lubricant, a taste masking agent, a dissolution aid, a suspending agent, a coating agent or any combination thereof.
7 . The method of claim 1 , wherein the cytidine and uridine, or cytidylic acid and uridylic acid, are formulated as a daily dosage of between about 1 mg to 800 gram per day.
8 . The method of claim 1 , wherein the formulation or pharmaceutical is formulated or mixed with a food or a drink product before administration to the individual in need thereof.
9 . The method of claim 8 , wherein the food or drink product is or comprises: a milk or a dairy product, a seasoning, a beverage, a confectionery, a bread, a noodle, an oils or a fat, a processed meat product, a processed marine product, a processed agricultural product, a frozen food or an instant food.
10 . The method of claim 9 , wherein the milk or dairy product is or comprises a milk powder.
11 . The method of claim 1 , wherein the cytidylic acid comprises:
(a) an alkali metal salt, optionally a sodium or a potassium salt;
(b) an alkaline earth metal salts, optionally a calcium, magnesium or barium salt;
(c) a basic amino acid salt, optionally an arginine or a lysine salt;
(d) an ammonium salt, optionally an ammonium or a tricyclohexylammonium salt;
(e) an alkanolamine salt, optionally a monoethanolamine salt, a diethanolamine salt or a triethanolamine salt,
(f) a monoisopropanolamine salt, a diisopropanolamine salt or a triisopropanolamine salt; or
(b) any combination of (a) to (e).
12 . The method of claim 11 , wherein the cytidylic acid comprises a monosodium cytidylate or a disodium cytidylate.
13 . The method of claim 1 , wherein the uridylic acid comprises:
(a) an alkali metal salt, optionally a sodium or a potassium salt;
(b) an alkaline earth metal salts, optionally a calcium, magnesium or barium salt;
(c) a basic amino acid salt, optionally an arginine or a lysine salt;
(d) an ammonium salt, optionally an ammonium or a tricyclohexylammonium salt;
(e) an alkanolamine salt, optionally a monoethanolamine salt, a diethanolamine salt or a triethanolamine salt,
(f) a monoisopropanolamine salt, a diisopropanolamine salt or a triisopropanolamine salt; or
(g) any combination of (a) to (e).
14 . The method of claim 13 , wherein the uridylic acid comprises a monosodium uridylic or a disodium uridylic.
15 . The method of claim 13 , wherein the muscular atrophy inhibited comprises skeletal muscle atrophy.
16 . A method for inhibiting a ubiquitin-proteasome proteolytic system in an individual in need thereof, wherein the method comprises:
(a) providing a formulation or pharmaceutical comprising:
(i) cytidine or a cytidylic acid salt;
(ii) uridine or uridylic acid salt;
(iii) cytidine and uridine; or
(iv) cytidylic acid or a cytidylic acid salt, and uridylic acid or a uridylic acid salt; and
(b) administrating to the individual in need thereof the formulation or pharmaceutical of (a).
17 . A method for inhibiting expression of an Atrogin-1 gene in an individual in need thereof, wherein the method comprises:
(a) providing a formulation or pharmaceutical comprising:
(i) cytidine or a cytidylic acid salt;
(ii) uridine or uridylic acid salt;
(iii) cytidine and uridine; or
(iv) cytidylic acid or a cytidylic acid salt, and uridylic acid or a uridylic acid salt; and
(b) administrating to the individual in need thereof the formulation or pharmaceutical of (a).
18 . The method of claim 1 , wherein active ingredients in the formulation or pharmaceutical consist of cytidine or a cytidylic acid salt.
19 . The method of claim 1 , wherein active ingredients in the formulation or pharmaceutical consist of uridine or uridylic acid salt.
20 . The method of claim 1 , wherein active ingredients in the formulation or pharmaceutical consist of cytidine and uridine.
21 . The method of claim 1 , wherein active ingredients in the formulation or pharmaceutical consist of cytidylic acid or a cytidylic acid salt, and uridylic acid or a uridylic acid salt.